Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
AssigneeChemoCentryx, Inc.
InventorsIsrael CHARO, Heiyoun JUNG, Thomas J. SCHALL, Penglie ZHANG
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.
Claims32
A method for treating a subject having a solid tumor cancer, said method comprising administering to the subject in need thereof a therapeutically effective amount of a CCR1 chemokine receptor antagonist, and a therapeutically effective amount of a PD-1 inhibitor or a PD-L1 inhibitor.
A composition for treating a subject having a solid tumor cancer, comprising a therapeutically effective amount of a CCR1 chemokine receptor antagonist, a therapeutically effective amount of a PD-1 inhibitor or a PD-L1 inhibitor, and a pharmaceutically acceptable carrier or excipient.
A kit for treating a subject having a solid tumor cancer, said kit comprising a therapeutically effective amount of a CCR1 chemokine receptor antagonist and a therapeutically effective amount of a PD-1 inhibitor or a PD-L1 inhibitor, with instruction for effective administration.
Dependencies are inferred from the claim text.